Lonafarnib

Vladimir Beljanski

doi:10.1016/B978-008055232-3.64492-7

Lonafarnib

Vladimir Beljanski

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Lonafarnib is a synthetic tricyclic derivative of carboxamide with antineoplastic properties. Lonafarnib binds to and inhibits farnesyl transferase, an enzyme involved in the post-translational modification and activation of Ras proteins. Ras proteins participate in numerous signaling pathways (proliferation, cytoskeletal organization), and play an important role in oncogenesis. Mutated Ras proteins have been found in a wide range of human cancers.. © 2009

Original language	English
Title of host publication	xPharm
Subtitle of host publication	The Comprehensive Pharmacology Reference
Editors	S.J. Enna, David B. Bylund
Publisher	Elsevier Inc.
Pages	1-4
Number of pages	4
ISBN (Print)	9780080552323
DOIs	https://doi.org/10.1016/B978-008055232-3.64492-7
State	Published - 2009
Externally published	Yes

ASJC Scopus Subject Areas

General Pharmacology, Toxicology and Pharmaceutics

Disciplines

Medicine and Health Sciences

Access to Document

10.1016/B978-008055232-3.64492-7

Cite this

@inbook{af47b9a6468447ccb2989ba425025fb0,

title = "Lonafarnib",

abstract = "Lonafarnib is a synthetic tricyclic derivative of carboxamide with antineoplastic properties. Lonafarnib binds to and inhibits farnesyl transferase, an enzyme involved in the post-translational modification and activation of Ras proteins. Ras proteins participate in numerous signaling pathways (proliferation, cytoskeletal organization), and play an important role in oncogenesis. Mutated Ras proteins have been found in a wide range of human cancers.. {\textcopyright} 2009",

author = "Vladimir Beljanski",

year = "2009",

doi = "10.1016/B978-008055232-3.64492-7",

language = "English",

isbn = "9780080552323",

pages = "1--4",

editor = "S.J. Enna and Bylund, \{David B.\}",

booktitle = "xPharm",

publisher = "Elsevier Inc.",

address = "United States",

}

TY - CHAP

T1 - Lonafarnib

AU - Beljanski, Vladimir

PY - 2009

Y1 - 2009

N2 - Lonafarnib is a synthetic tricyclic derivative of carboxamide with antineoplastic properties. Lonafarnib binds to and inhibits farnesyl transferase, an enzyme involved in the post-translational modification and activation of Ras proteins. Ras proteins participate in numerous signaling pathways (proliferation, cytoskeletal organization), and play an important role in oncogenesis. Mutated Ras proteins have been found in a wide range of human cancers.. © 2009

AB - Lonafarnib is a synthetic tricyclic derivative of carboxamide with antineoplastic properties. Lonafarnib binds to and inhibits farnesyl transferase, an enzyme involved in the post-translational modification and activation of Ras proteins. Ras proteins participate in numerous signaling pathways (proliferation, cytoskeletal organization), and play an important role in oncogenesis. Mutated Ras proteins have been found in a wide range of human cancers.. © 2009

UR - https://www.scopus.com/pages/publications/84884046535

UR - https://www.scopus.com/pages/publications/84884046535#tab=citedBy

U2 - 10.1016/B978-008055232-3.64492-7

DO - 10.1016/B978-008055232-3.64492-7

M3 - Chapter

AN - SCOPUS:84884046535

SN - 9780080552323

SP - 1

EP - 4

BT - xPharm

A2 - Enna, S.J.

A2 - Bylund, David B.

PB - Elsevier Inc.

ER -

Lonafarnib

Abstract

ASJC Scopus Subject Areas

Disciplines

Access to Document

Other files and links

Fingerprint

Cite this